10-Q: Harvard Bioscience Faces Going Concern Doubt Amid Losses

Harvard Bioscience reported a significant net loss driven by a goodwill impairment and faces substantial doubt about its ability to continue as a going concern due to debt obligations and Nasdaq delisting risk.

Summary

• Reported a net loss of $52.622 million for the six months ended June 30, 2025, significantly wider than the $7.621 million loss in the prior year period, primarily due to a $47.951 million goodwill impairment charge.
• Revenues decreased by 11.3% to $42.224 million for the six months ended June 30, 2025, compared to $47.609 million in the same period last year, attributed to softening demand from academic research institutions and CROs, and tariff impacts.
• Gross profit declined by 15.3% to $23.717 million for the six months, with gross margin decreasing to 56.2% from 58.8%.
• Operating expenses, excluding goodwill impairment, saw reductions: Sales and marketing decreased by 15.8% to $9.510 million, General and administrative by 18.9% to $9.447 million, and Research and development by 18.2% to $4.510 million for the six-month period.
• Cash and cash equivalents increased to $7.442 million as of June 30, 2025, from $4.108 million at December 31, 2024, with net cash provided by operating activities significantly improving to $5.741 million for the six months.
• The company was not in compliance with certain refinancing milestones and financial covenants under its Credit Agreement as of June 30, 2025, but received a waiver from lenders through an August 2025 Amendment.
• The August 2025 Amendment increased the interest rate margin on debt to SOFR plus 700 basis points and requires steps towards refinancing or repayment by December 5, 2025.
• Received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement, with a compliance period until October 1, 2025.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'substantial doubt about going concern,' a massive goodwill impairment, ongoing debt covenant non-compliance requiring waivers, and the Nasdaq delisting threat. While operational expenses were cut and cash from operations improved, these positives are overshadowed by fundamental solvency and liquidity challenges.

Positives

• Net cash provided by operating activities significantly improved to $5.741 million for the six months ended June 30, 2025, compared to $0.557 million in the prior year.
• Cash and cash equivalents increased to $7.442 million as of June 30, 2025, from $4.108 million at December 31, 2024.
• Operating expenses (Sales & Marketing, G&A, R&D) were reduced for both the three and six-month periods ended June 30, 2025.
• Lenders provided a waiver for non-compliance with certain debt covenants and refinancing milestones as of June 30, 2025.
• Regained compliance with Nasdaq Listing Rule 5605(c)(2)(A) regarding Audit Committee composition.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to debt obligations and uncertain access to capital.
• Reported a significant net loss of $52.622 million for the six months ended June 30, 2025, primarily due to a $47.951 million non-cash goodwill impairment charge.
• Revenues decreased by 11.5% for the three months and 11.3% for the six months ended June 30, 2025, driven by softening demand and tariffs.
• Gross profit and gross margin declined for both the three and six-month periods.
• Non-compliance with debt refinancing milestones and financial covenants as of June 30, 2025, necessitating a waiver.
• Interest rate margin on debt increased to SOFR plus 700 basis points following the August 2025 Amendment.
• Received a Nasdaq notice for non-compliance with the $1.00 minimum bid price requirement, risking delisting.
• Identified material weaknesses in internal control over financial reporting related to the order-to-cash cycle and physical inventory counts, which are not yet remediated.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to insufficient cash flow to pay debt obligations and fund operations without accessing additional capital or extending repayment dates.
• Failure to accomplish steps towards refinancing or repayment of the Credit Agreement by December 5, 2025, will constitute an event of default, potentially making outstanding amounts immediately due and payable.
• Uncertainty regarding the availability of alternative sources of capital on commercially acceptable terms to refinance outstanding indebtedness.
• Risk of delisting from Nasdaq due to non-compliance with the $1.00 minimum bid price requirement, which could negatively impact the stock price, liquidity, and ability to raise capital.
• Potential for additional goodwill impairment charges if the stock price, operating results, macroeconomic conditions, or cost of capital further deteriorate.
• Continued softening of worldwide demand from academic research institutions and CROs, and the ongoing impact of reciprocal tariffs, could further affect revenue.
• Material weaknesses in internal control over financial reporting could lead to undetected misstatements and adversely affect financial reporting reliability.
• Employee retention tax credit refunds are subject to audit until May 2028, posing a risk of future adjustments.

Future Outlook

The company is actively exploring alternative sources of capital to refinance its outstanding indebtedness under the Credit Agreement, with a deadline of December 5, 2025, to accomplish steps towards refinancing or repayment. Management expects to continue efforts throughout fiscal year 2025 to remediate identified material weaknesses in internal control over financial reporting. The company also intends to monitor its common stock bid price and consider options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement by October 1, 2025.

Management Comments

• The report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
• The financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
• We are responsible for establishing and maintaining disclosure controls and procedures, and internal control over financial reporting, and have designed such controls to ensure material information is known and to provide reasonable assurance regarding financial reporting reliability.
• We have evaluated the effectiveness of disclosure controls and procedures and presented conclusions about their effectiveness as of the end of the period covered by this report.
• We have disclosed any change in internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.
• We have disclosed, based on our most recent evaluation of internal control over financial reporting, to the auditors and audit committee, all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, and any fraud involving management or other employees with a significant role in internal control over financial reporting.

Industry Context

The company's business is significantly affected by global and regional economic trends and uncertainties. Revenue has been impacted by customers delaying or forgoing purchases due to ongoing uncertainty regarding funding levels and timing from sources like the U.S. National Institutes of Health (NIH). Additionally, increased tariffs on international trade, particularly between the United States and China, have negatively affected revenue and increased costs. The life sciences industry as a whole is experiencing challenging macroeconomic conditions, contributing to the company's recent operating results and liquidity risks.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is occasionally subject to claims and lawsuits arising in the normal course of business, but management does not believe the outcome of any current matters will have a material adverse effect on the company's business, results of operations, financial condition, or cash flows.

Stakeholder Impact

• **Shareholders**: Face significant risk of value erosion due to substantial net losses, goodwill impairment, potential Nasdaq delisting, and uncertainty surrounding the company's ability to continue as a going concern. A reverse stock split, if pursued, could also have unpredictable effects on share price.
• **Lenders**: The company's non-compliance with debt covenants and the need for waivers, coupled with an increased interest rate on outstanding debt, indicates heightened risk for creditors. The requirement for refinancing or repayment by December 5, 2025, puts pressure on the company's ability to meet its obligations.
• **Employees**: Restructuring activities, including headcount reductions in North America and Europe, indicate potential job insecurity and impact on employee morale.
• **Customers**: Softening worldwide demand from academic research institutions and CROs suggests a challenging market environment, potentially impacting future sales and product availability.
• **Suppliers**: Reduced sales volumes and potential liquidity issues could impact the company's ability to maintain consistent order volumes or timely payments to suppliers.

Next Steps

• Accomplish steps towards refinancing or repayment of the Credit Agreement by December 5, 2025.
• Continue efforts to remediate material weaknesses in internal control over financial reporting throughout fiscal year 2025.
• Actively monitor the common stock bid price and consider available options, including effecting a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement by October 1, 2025.

Key Dates

Recommendation

The filing reveals severe financial distress, including 'substantial doubt about the company's ability to continue as a going concern,' a massive goodwill impairment charge, and persistent revenue decline. Despite a waiver on debt covenants, the company faces an imminent deadline to refinance or repay its debt under significantly higher interest rates. The Nasdaq delisting threat further compounds the risk, indicating a potential loss of liquidity and investor confidence. While operational cost reductions are noted, they are insufficient to offset the fundamental challenges to the company's viability. This combination of factors presents an extremely high-risk profile, making the stock a strong sell for any seasoned investor or institution.

Keywords

Life Sciences, Biotechnology, Research Tools, SEC Filing, 10-Q, Financial Performance, Goodwill Impairment, Going Concern, Debt Restructuring, Nasdaq Delisting, Financial Covenants, Cash Flow, Revenue Decline, Internal Controls